AzTrials
AzTrials

Obstructive Sleep ApneaNCT05134402

Recording of Multiple Nights Using a New Contactless Device (Sleepiz One Connect) in Obstructive Sleep Apnea

An observational study of Obstructive Sleep Apnea and Sleep Apnea, run by Samuel Tschopp at 1 site in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The need for multiple night testing is well recognized in sleep medicine because of a considerable and relevant night-to-night variability. In a study with multiple recordings using WatchPAT®, the OSA severity of 24% of patients was misclassified when using one night compared to the average of three nights. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Sleepiz One Connect
How many people
25 participants
Where
1 siteSwitzerland
Study dates
1 Dec 2021to 31 Dec 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with suspected obstructive sleep apnea will be eligible for this study.

Who may be able to join

  • Age ≥ 18yrs
  • Obstructive Sleep Apnea (OSA) defined as AHI ≥ 5/h
  • Consecutive recordings are possible over 10 nights within 3 weeks
  • Informed consent

Who cannot join

  • Age <18yrs
  • No obstructive sleep apnea AHI < 5/h
  • Central sleep apnea events > 25%
  • Patients with implanted active devices (e.g pacemakers, neurostimulators)
  • Multiple night recordings are not possible
  • Insufficient language comprehension in German
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • Canton Hospital Baselland, Klinik für Hals-, Nasen- und Ohrenkrankheiten

    Liestal, 4410

Other trials in Switzerland

About this study

The need for multiple night testing is well recognized in sleep medicine because of a considerable and relevant night-to-night variability. In a study with multiple recordings using WatchPAT®, the OSA severity of 24% of patients was misclassified when using one night compared to the average of three nights. On average, pAHI varied by 57% from night-to-night. The variability of pAHI could partially be explained by the variability of time spent in the supine position with more time supine leading to a higher pAHI (Tschopp et al 2021). Smith (2007) suggested that the AHI should be indicated with a confidence interval to indicate the uncertainty regarding its true value. The Minimal Detectable Difference (MDD) is of special interest in sleep medicine, especially when assessing treatment effects. MDD was found to be 12.8/h and the standard error of measurement was 4.6/h for 4 nights of polysomnography (Aarab et al. 2008). For WatchPAT®, measuring two and three nights showed a small reduction in MDD from 19.1/h to 18.0/h (Tschopp et al. 2021, in press). Only one study using pulse oximetry assessed the night-to-night variability over 14 days (Stöberl A. et al 2017). The study confirmed the enormous variability and focused mainly on its impact on OSA severity.

While the night-to-night variability has been extensively studied for polysomnography, respiratory polygraphy, and WatchPAT®, little is known about the optimal number of nights to be recorded. There is convincing evidence from the literature, that the recording of multiple nights is the only way to assess the severity of the patient's disease with clinically reasonable accuracy. Moreover, the MDD with only one night's recording is astonishingly high. The question is how many nights should be recorded to achieve acceptable diagnostic accuracy. The precision of the OSA measurement depends on the clinical situation. For example, to diagnose severe OSA, a higher variability might be acceptable without influencing the treatment decision. However, when comparing treatment effects, the MDD should be as small as possible. The recording of multiple nights might be cumbersome for patients (e.g. with polysomnography or respiratory polygraphy) as well as costly. These factors have to be taken into consideration for the clinically feasible number of recordings.

Read more

Sleepiz One Connect offers the unique opportunity for a contactless recording of breathing combined with conventional pulse oximetry and is a minimally invasive diagnostic tool that allows measurements over several nights. Studies with multiple night recordings will offer a basis for diagnostic recommendations in future guidelines.

The study aims to investigate the variability of obstructive sleep apnea at-home sleep apnea testing. By investigating the variability, we want to quantify the improvement in diagnostic accuracy by additional measurements.

The hypothesis is that additional recordings offer a significant improvement in diagnostic accuracy by reducing the variability. The reduction in variability will diminish with each additional recording.

Being tested
Sleepiz One Connect
Keywords
night-to-night variability, home sleep apnea testing, upper airway
Medical subject headings
Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Respiratory Tract Diseases, Respiration Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sleepiz One ConnectDiagnostic test

    Sleepiz One Connect measurements over 10 nights

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intraclass Correlation Coefficient (ICC) of apnea-hypopnea index

    ICC and conficence intervall

    Measured: 10 nights

Secondary outcomes (4)
  1. Misclassification rate of obstructive sleep apnea

    misclassification rate by night compared to average

    Measured: 10 nights

  2. Minimal Detectable Difference

    as difference in apnea-hypopnea index

    Measured: 10 nights

  3. False-positive responder rate

    yes or no

    Measured: 10 nights

  4. Patient comfort

    VAS 0-10

    Measured: 10 nights

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Nov 2021
  2. Study start1 Dec 2021
  3. Primary completion31 Dec 2022
  4. Study completion31 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
25 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05134402
Sponsor's protocol ID
2021-01564
Status last verified
Oct 2023
First submitted
13 Nov 2021
Last updated
10 Oct 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Tschopp S, Borner U, Caversaccio M, Tschopp K. Long-term night-to-night variability of sleep-disordered breathing using a radar-based home sleep apnea test: a prospective cohort study. J Clin Sleep Med. 2024 Jul 1;20(7):1079-1086. doi: 10.5664/jcsm.11070.

    PubMed 38415722

Questions about this trial

What is this clinical trial studying?

An observational study of Obstructive Sleep Apnea and Sleep Apnea, run by Samuel Tschopp at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intraclass Correlation Coefficient (ICC) of apnea-hypopnea index (time frame: 10 nights). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05134402, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in